Jaguar Animal Health (NASDAQ:JAGX) Issues Quarterly Earnings Results

Jaguar Animal Health (NASDAQ:JAGX) released its earnings results on Friday. The biotechnology company reported ($6.28) earnings per share for the quarter, missing the consensus estimate of ($5.08) by ($1.20), FiscalAI reports. The company had revenue of $3.08 million during the quarter, compared to analyst estimates of $3.73 million. Jaguar Animal Health had a negative net margin of 344.16% and a negative return on equity of 660.18%.

Jaguar Animal Health Stock Up 4.7%

Shares of NASDAQ JAGX traded up $0.08 during mid-day trading on Friday, reaching $1.78. 55,507 shares of the company’s stock were exchanged, compared to its average volume of 75,054. Jaguar Animal Health has a twelve month low of $1.57 and a twelve month high of $33.25. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 2.44. The firm has a market capitalization of $3.87 million, a price-to-earnings ratio of -0.03 and a beta of 0.50. The business has a fifty day simple moving average of $2.00 and a 200 day simple moving average of $3.17.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $60.00.

About Jaguar Animal Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.